LuciBaric baricitinib 2mg

Product Information

• Catalog product: Lucius LuciBaric Baricitinib 2mg
• Listed manufacturer: Lucius Pharma, Laos
• Active ingredient and strength: baricitinib, 2mg
• AISTIKA SKU: LU-ITEM-1

Product Summary

LuciBaric is the Lucius baricitinib 2mg item in this catalog. The 2mg strength is part of the product identity, not a recommendation that every person should take that amount. Match the name, strength, manufacturer and SKU when checking this listing against a prescription or product request.

Active Ingredient and Reference Data

The clinical reference is the active ingredient’s US labeling, updated October 9, 2026. Public labels for another brand do not establish LuciBaric’s local authorization, quality or interchangeability. European indications differ, so do not combine countries’ labels into one universal indication list.

Mechanism of Action

Baricitinib inhibits JAK1 and JAK2 signaling involved in immune responses. It is an immunomodulating medicine, not a conventional painkiller, and a product listing cannot establish whether suppressing these pathways is appropriate for a particular person.

Reference Indications

The US label includes adults with moderately to severely active rheumatoid arthritis after inadequate response to TNF blockers; severe alopecia areata from age 12; and hospitalized adults with COVID-19 requiring oxygen or ventilatory support. This is not a home-COVID-treatment recommendation.

Reference Dosage and Administration

The adult rheumatoid-arthritis reference dosage is 2mg once daily: one 2mg tablet when prescribed. Other indications and kidney impairment require different decisions. A physician must select the regimen; a pharmacist must check the supplied insert.

Important Safety Information

FDA warnings address serious infections, malignancy, cardiovascular events, blood clots and mortality. Tell the clinician about smoking, cardiovascular disease, previous thrombosis or cancer. Seek emergency care for possible heart attack, stroke or clot symptoms. The risks require an individual benefit-risk assessment, not selection by price or strength alone.

Common Adverse Reactions and Monitoring

Common reported effects include respiratory infections, nausea and herpes infections. Clinicians assess TB risk, blood counts, liver tests, lipids and kidney function. Avoid live vaccines during treatment. Discuss the monitoring plan before starting therapy.

Drug Interactions and Special Populations

Probenecid and other strong OAT3 inhibitors affect dosing. Combining with other JAK inhibitors, biologic immunomodulators or potent immunosuppressants is not recommended. Pregnancy and breastfeeding require medical review.

Storage and Purchase Notes

Follow the storage instructions on the supplied LuciBaric pack. Confirm the pack count, expiry, batch and insert separately; a photograph and a 2mg strength do not supply these details. The price and availability on this page apply to this catalog item, not a guaranteed treatment cost or promise of delivery to every destination.

Medical information basis: official public product labeling and regulatory safety information.

Disclaimer

Educational catalog information only. This is not an individualized prescription, a guarantee of treatment response or evidence of local approval or therapeutic equivalence for LuciBaric. Consult a qualified physician or pharmacist before starting, switching or adjusting treatment.